Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Gandara DR , Aparicio A, Somlo G. A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid, -SAHA) in Metastatic Breast Cancer: A California Cancer Consortium Study. Clin Can Res. 2008 Accepted.
Somlo G, Chu P, Frankel P, Ye W, Groshen S, Doroshow J, Danenberg K, Danenberg P. Molecular Profiling Including Epidermal Growth Factor Receptor and p21 Expression in High-Risk Breast Cancer Patients as Indicators of Outcome. Ann Oncol 2008. Accepted.
Pal SK, Blaser K, Weitzel J, and Somlo, G. An Association between Invasive Breast Cancer and Familial Idiopathic Hyperparathyroidism: A Case Series and Review of the Literature. Breast Cancer Res Treat. 2008 May 26 Epub.
Lowe T, Bhatia S and Somlo G. Second malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 13:1121-34, 2007.
Hurria A, Somlo G. and Ahles T. Renaming “chemobrain”. Cancer Invest. 25: 373-7, 2007.
Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G., et al. Invasive breast cancer. J Natl Compr Canc Netw. 5: 246-312, 2007.
Marsh S, Somlo G., Li X, Frankel P, King CR, Shannon WD, McLeod HL, Synold RTW. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics 7: 362-5, 2007. Epub 2007 Jan 16.
Schultheiss T, Wong J, Liu A, Olivera G, Somlo G. Image-guided total marrow and total lymphatic irradiation using helical tomotherapy. Int J Radiat Oncol Biol Phys. 67:1258-67, 2007.
Smith TJ Chair, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. J Clin Oncol., 24: 187-205, 2006.
Somlo, G., Frankel, P., Chow, W., Leong, L., Margolin, K., Morgan, R., Shibata, S., Chu, P., Forman, S., Lim, D., Twardowski, P., Weitzel, J., Alvarnas, J., Kogut, N., Schriber, J., Fermin, E., Damon, L., and Doroshow, J.H. Prognostic indicators and survival in 120 patients with stage IIIB inflammatory breast carcinoma following dose-intensive chemotherapy. J. Clin. Oncol. 22: 1839-1848, 2004.
Openshaw, H., Beamon, J., Synold, T.W., Longmate, J., Slatkin, N.E., Doroshow, J.H., Forman, S., Margolin, K., Morgan, R., Shibata, S., and Somlo, G. Neurophysiological study of peripheral neuropathy after high-dose paclitaxel: Lack of Neuroprotective effect of amifostine. Clin. Cancer Res. 10: 461-467, 2004.
Somlo, G., Simpson, J.F., Frankel, P., Chow, W., Leong, L., Margolin, K., Morgan, R. Jr., Raschko, J., Shibata, S., Forman, S., Kogut, N.., McNamara, M., Molina, A., Somlo, E., and Doroshow, J.H. Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Brit. J. Cancer 87(3): 281-288, 2002.
Somlo, G., Doroshow, J.H., Synold, T., Longmate, J., Reardon, D., Chow, W., Forman, S.J., Leong, L.A., Margolin, K.A., Morgan, R.J., Jr., Raschko, J.W., Shibata, S.I., Tetef, M.L., Yen, Y., Kogut, N., Schriber, J., and Alvarnas, J. High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome. Brit. J. Cancer 84: 1591-1598, 2001.
Somlo, G., Doroshow, J.H., ter Veer, A., Longmate, J., Chow, W., Hamasaki, V., Leong, L., Margolin, K., Morgan, Jr., R., Raschko, J., Shibata, S., O’Donnell, M., Smith, E., Tetef, M., Forman, S., Yen, Y., Molina, A., and Sniecinski, I. Tandem cycle of high dose melphalan and cisplatin with peripheral blood progenitor cell support for patients with breast cancer and other malignancies. Biol. Blood Marrow Transplant 7: 284-293, 2001.
Somlo, G., Sniecinski, I., ter Veer, A., Longmate, J., Vuk-Pavlovic, S., Chow, W., Leong, L., Morgan, R., Margolin, K., Raschko, J., Shibata, S., Tetef, M., Yen, Y., Forman, S., Jones, D., Asby, M., Fyfe, G., Hellmann, S., and Doroshow, J. Recombinant human thrombopoietin in combination with GCSF enhances moblization of peripheral blood progenitor cells, increases peripheral blood platelet concentration and accelerates hematopoietic recovery following high-dose chemotherapy. Blood 93: 2798-2806, 1999.
Somlo, G., Doroshow, J., Forman, S., Marvon, T., Lee, J., Chow, W., Hamasaki, V., Leong, L., Morgan, R., Margolin, K., Raschko, J., Shibata, S., Tetef, M., Yen, Y., et al. High-Dose Chemotherapy and Stem Cell Rescue in the Treatments of High-Risk Breast Cancer: Prognostic Indicators of Progression-Free and Overall Survival. J. Clin. Oncol., 15: 2882-2893, 1997.
Somlo, G., Sniecinski, I., Odom-Maryon, T., Nowicki, B., Chow, W., Hamasaki, V., Leong, L., Margolin, K., Morgan, Jr., R., Raschko, J., Shibata,S., Tetef, M., Molina, A., Berenson, R.J., Forman, S.J., and Doroshow, J.H. Effect of CD34+ Selection and various Schedules of Stem Cell Reinfusion and Granulocyte Colony-Stimulating FactorPriming on Hematopoietic Recovery After High-Dose Chemotherapy for Breast Cancer. Blood 89: 1521-1528, 1997.
Margolin, K., Doroshow, J.H., Hamasaki, V., Leong, L., Morgan, Jr., R., Raschko, J., Shibata, S., Somlo, G., and Tetef, M. Treatment of Germ Cell Cancer with Two Cycles of High-Dose Ifosfamide, Carboplatin and Etoposide with Autologous Stem Cell Support. J. Clin. Oncol. 14: 2631-2637, 1996
Somlo, G., Doroshow, J.H., Lev-Ran, A., Ahn, D.C., Hwang, L., Raschko, J.W., Forman, S.J., Margolin, K.A., Morgan, R.J., Leong L.A., Hamasaki, V.K., Chow, W.A., Molina, A., Ahman, S.A., Kojian, A., and Menard, P. Effect of Low-Dose Prophylactic Dopamine on High-Dose Cisplatin-Induced Electrolyte Wasting, Ototoxicity, and Epidermal Growth Factor Excretion: A Randomized, Placebo-Controlled, Double-Blind Trial. J. Clin. Oncol. 13: 1231-1237, 1995.
This is an abbreviated document. Full CV available upon request. Information on this page may be self-reported and is subject to change at any time. Last updated: 06/08.
